Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CS6 BSIgG in ETEC Challenge
NCT03040687Phase 1Completed
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
- Start
- Jan 2017
- Primary completion
- Apr 2017
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of anti-CS6 BSIgG in enterotoxigenic Escherichia coli infection (3 arms), sponsored by Johns Hopkins Bloomberg School of Public Health. Primary endpoints: Safety of Serum Derived Bovine Immunoglobulins (BSIgG) at 28 days and Efficacy of B7A and CS6- Hyperimmune Bovine Serum Immunoglobin to Protect Against Moderate to Severe Diarrhea at 28 days. Started Jan 2017; status: completed.
02
Drugs
anti-CS6 BSIgG
03
Conditions
enterotoxigenic Escherichia coli infection
Beyond the preview
Go deeper on NCT03040687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03040687.